Table 3.

Relative risk estimates for clinical outcomes during and after the first 6 months of warfarin exposure

Clinical outcomes
INR	Before 6 months		After 6 months
	Relative risk	p-value	Relative risk	p-value
ACS
<2	6.6505	<0.0001	4.3918	<0.0001
>3	0.8847	0.4645	0.7998	0.5357
Ischemic stroke
<2	6.8189	<0.0001	2.9368	<0.0001
>3	0.5362	0.0090	0.4596	0.0967
Transient ischemic attack
<2	8.9904	<0.0001	1.8577	0.0768
>3	0.8693	0.7378	0.2505	0.1769
Systemic embolism
<2	4.8545	<0.0001	4.5573	0.0067
>3	0.2138	0.0338	1.8882	0.4476
Major bleeding
<2	2.0007	<0.0001	3.0921	<0.0001
>3	1.4562	0.0120	1.5150	0.0555

INR 2–3 = Reference group

ACS acute coronary syndrome, INR international normalized ratio